OncoCyte Co. (NYSEAMERICAN:OCX) saw a significant increase in short interest in the month of January. As of January 12th, there was short interest totalling 570,212 shares, an increase of 19.5% from the December 29th total of 477,222 shares. Based on an average trading volume of 26,062 shares, the short-interest ratio is currently 21.9 days. Currently, 6.8% of the shares of the company are short sold.
Shares of OncoCyte (OCX) traded up $0.05 during trading hours on Wednesday, hitting $4.45. The stock had a trading volume of 8,400 shares, compared to its average volume of 21,913. OncoCyte has a 12 month low of $3.60 and a 12 month high of $7.85. The company has a market capitalization of $131.99 and a PE ratio of -7.18.
OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01.
A number of brokerages have recently issued reports on OCX. ValuEngine cut OncoCyte from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Zacks Investment Research cut OncoCyte from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/24/oncocyte-co-ocx-short-interest-update.html.
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.